The historical rank and industry rank for Oncternal Therapeutics's Price-to-Free-Cash-Flow or its related term are showing as below:
FRA:GTU's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.69 * Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 14.10% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 40.80% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 37.70% per year.
During the past 13 years, Oncternal Therapeutics's highest 3-Year average Free Cash Flow per Share Growth Rate was 64.20% per year. The lowest was -53.30% per year. And the median was 22.70% per year.
Oncternal Therapeutics Price-to-Free-Cash-Flow Historical Data
The historical data trend for Oncternal Therapeutics's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oncternal Therapeutics's Price-to-Free-Cash-Flow
For the Biotechnology subindustry, Oncternal Therapeutics's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncternal Therapeutics's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Oncternal Therapeutics's Price-to-Free-Cash-Flow falls into.
Oncternal Therapeutics's Share Price of today is €5.32. Oncternal Therapeutics's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-8.97.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Oncternal Therapeutics Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Oncternal Therapeutics's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncternal Therapeutics (FRA:GTU) Business Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:GTU has been successfully added to your 